

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau

(43) International Publication Date  
16 January 2025 (16.01.2025)



(10) International Publication Number  
**WO 2025/012415 A1**

(51) International Patent Classification:

A61K 38/16 (2006.01) A61P 13/12 (2006.01)  
A61K 31/56 (2006.01)

LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,  
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,  
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:

PCT/EP2024/069757

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))
- in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE

(22) International Filing Date:

11 July 2024 (11.07.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

23306197.7 12 July 2023 (12.07.2023) EP

(71) Applicants: COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES [FR/FR]; 25 rue Leblanc Bat le Ponant, 75015 PARIS (FR). INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE [FR/FR]; 101, rue de Tolbiac, 75013 PARIS (FR).

(72) Inventors: DANG, Julien; 230 boulevard Pasteur, 94360 BRY SUR MARNE (FR). GILLET, Daniel; 3 rue Jean-Charles Persil, 92160 ANTONY (FR). MAHTAL, Nassim; 273 rue d'Epinay, 95360 MONTMAGNY (FR). PICHARD, Sylvain; 43 rue des Norottes, 91310 LEUVILLE SUR ORGE (FR). THARAUX, Pierre Louis; 15, rue des Garrements, 92140 CLAMART (FR).

(74) Agent: PLASSERAUD IP; 104 rue de Richelieu CS92104, 75080 PARIS CEDEX 02 (FR).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,

(54) Title: COMBINATION OF A HB-EGF INHIBITOR AND A CORTICOSTEROID AGENT FOR THE TREATMENT OF KIDNEY DISEASES ASSOCIATED WITH ACTIVATION OF THE HB-EGF/EGFR PATHWAY

(57) Abstract: The invention relates to a combination of a corticosteroid agent and an inhibitor of Heparin- Binding Epidermal Growth Factor-like growth factor (HB-EGF) for use in the treatment of kidney diseases associated with the activation of the HB-EGF/EGF receptor pathway.

WO 2025/012415 A1